Roche Holding AG (ETR:RHO)
Germany · Delayed Price · Currency is EUR | Market Cap | 282.64B +17.8% |
| Revenue (ttm) | 68.05B +1.5% |
| Net Income | 13.83B +55.6% |
| EPS | 17.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.43 |
| Forward PE | 16.04 |
| Dividend | 11.96 (3.36%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 243 |
| Average Volume | 297 |
| Open | 353.60 |
| Previous Close | 353.20 |
| Day's Range | 353.40 - 363.60 |
| 52-Week Range | 272.60 - 420.80 |
| Beta | n/a |
| RSI | 52.68 |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche CEO: Obesity drug pipeline could challenge market leaders
Thomas Schinecker, CEO at Roche discusses Q1 earnings, and explains the timeline behind the company's launch of their GLP-1 drug offering.
Europe risks falling further behind in medicine race, warns Roche CEO
Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief E...
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche sales fell 5% in the first quarter, but increased 6% in constant exchange rates. The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on...
Roche Backs Full-Year View as Quarterly Sales Rise
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmac...
Roche's ENSPRYNG Cuts Relapse Risk In Rare Neurological Disease
(RTTNews) - Roche (RHHBY) yesterday announced new results from its Phase III METEOROID study showing that ENSPRYNG reduced the risk of relapse by 68% compared to placebo in patients with myelin oligod...
Genentech's Fenebrutinib Slashes Relapses By Over 50% In RMS , But Safety Signals Cast A Shadow
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), reported positive data for Fenebrutinib, its investigational candidate from the Phase 3, FENhance 1 and 2 studies in relapsing multiple scle...
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals while data released on Wednes...
Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Basel, 22 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that feneb...
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which ...
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple scleros...
Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple scleros...
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 6...
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspry...
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) MOGAD is a rare autoimmune disease of the central nervous sy...
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) MOGAD is a rare autoimmune disease of the central nervous sy...
Roche's Gazyva/Gazyvaro SBLA For SLE Accepted By FDA; Decision Slated For December 2026
(RTTNews) - The FDA has accepted Roche's (RHHBY) supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro as a potential new treatment for systemic lupus erythematosus (SLE), the most com...
Roche (RHHBY) Advances Gazyva/Gazyvaro for Lupus Treatment with FDA Filing
Roche (RHHBY) Advances Gazyva/Gazyvaro for Lupus Treatment with FDA Filing
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupus
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the compa...
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus
Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) If approved, G...
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupus
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) If ap...